Female Reproductive System Carcinoma — Trials

Female Reproductive System Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

1,481 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 458
Recruiting: 230
Ph III recruiting: 25
Growth YoY: +35.3%
Industry share: 26%
Top sponsor: National Cancer Institute (NCI)
Termination share: 34.3%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (201)

clinicaltrialsPublishedShowing 51–100 of 279 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03067181	Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors	recruiting	Phase 3	1,780	Children's Oncology GroupNETWORK	9	Aug 25, 2026	clinicaltrials
NCT04851119	Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors	recruiting	Phase 1 / Phase 2	147	Children's Oncology GroupNETWORK	1	Aug 25, 2026	clinicaltrials